Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 12, Issue 3, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-05
DOI
10.1038/s41419-021-03535-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ursodeoxycholic Acid Inhibits Glioblastoma Progression via Endoplasmic Reticulum Stress Related Apoptosis and Synergizes with the Proteasome Inhibitor Bortezomib
- (2020) Zhong Yao et al. ACS Chemical Neuroscience
- Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles
- (2020) Ming-yue Chen et al. JOURNAL OF NANOBIOTECHNOLOGY
- Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer
- (2020) Jianjun Qi et al. Cell Death & Disease
- An old medicine as a new drug to prevent mitochondrial complex I from producing oxygen radicals
- (2019) Dominique Detaille et al. PLoS One
- Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling
- (2019) Yujie Li et al. ARCHIVES OF TOXICOLOGY
- Effects of the antifungal agent ciclopirox in HPV‐positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis
- (2019) Julia A. Braun et al. INTERNATIONAL JOURNAL OF CANCER
- Deferoxamine suppresses esophageal squamous cell carcinoma cell growth via ERK1/2 mediated mitochondrial dysfunction
- (2018) Linhua Lan et al. CANCER LETTERS
- Proliferative Glioblastoma Cancer Cells Exhibit Persisting Temporal Control of Metabolism and Display Differential Temporal Drug Susceptibility in Chemotherapy
- (2018) Paula M. Wagner et al. MOLECULAR NEUROBIOLOGY
- Arginylated Calreticulin Increases Apoptotic Response Induced by Bortezomib in Glioma Cells
- (2018) Andrea Comba et al. MOLECULAR NEUROBIOLOGY
- Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR–CHK1, p21, and NF-κB
- (2018) Dorthe Aasland et al. CANCER RESEARCH
- A radical shift in perspective: mitochondria as regulators of reactive oxygen species
- (2017) Daniel Munro et al. JOURNAL OF EXPERIMENTAL BIOLOGY
- FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development
- (2017) Sanjeeb Kumar Sahu et al. Nature Communications
- Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models
- (2017) Chrysovalantou Mihailidou et al. Oncotarget
- Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma
- (2016) Xing Bao et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Downregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK/p38MAPK signaling and reducing cellular bioenergetics
- (2016) Deyao Xie et al. Oncotarget
- The Keap1-Nrf2-antioxidant response element pathway: A review of its regulation by melatonin and the proteasome
- (2015) Jerry Vriend et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies
- (2013) Mark D. Minden et al. AMERICAN JOURNAL OF HEMATOLOGY
- Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF- B
- (2013) L. Bastian et al. CLINICAL CANCER RESEARCH
- Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
- (2013) Panagiotis J. Vlachostergios et al. INVESTIGATIONAL NEW DRUGS
- Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia
- (2013) D Koyama et al. LEUKEMIA
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
- (2012) Y. H. Messinger et al. BLOOD
- Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro
- (2012) Chongmei Huang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling
- (2012) Alfeu Zanotto-Filho et al. INVESTIGATIONAL NEW DRUGS
- Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF- B Signaling Pathway
- (2011) E. P. Jane et al. MOLECULAR CANCER THERAPEUTICS
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
- (2010) J. J. Wright CLINICAL CANCER RESEARCH
- The antitumor activity of the fungicide ciclopirox
- (2010) Hongyu Zhou et al. INTERNATIONAL JOURNAL OF CANCER
- Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer
- (2010) Evette S. Radisky et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- The NF- B Family of Transcription Factors and Its Regulation
- (2009) A. Oeckinghaus et al. Cold Spring Harbor Perspectives in Biology
- Is NF-κB a good target for cancer therapy? Hopes and pitfalls
- (2008) Véronique Baud et al. NATURE REVIEWS DRUG DISCOVERY
- Ciclopirox for the treatment of superficial fungal infections: a review
- (2003) Aditya K. Gupta et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search